🏳️‍🌈 Anal Cancer and the LGBTQ+ Community — The Risk Most People Don't Know About

Anal cancer is one of the least discussed cancers in public health conversation — and one of the most relevant to the LGBTQ+ community, particularly gay and bisexual men and people living with HIV. The gap between how common it is in certain populations and how rarely it's talked about is significant — and it has real consequences for prevention and early detection.

Here's what the evidence shows, and why it matters.

What is anal cancer?

Anal cancer is a malignancy that develops in the tissues of the anus — the opening at the end of the digestive tract. It is distinct from colorectal cancer, which develops higher up in the colon or rectum.

Anal cancer is relatively rare in the general population — but within specific groups, the rates are significantly elevated. And unlike many cancers, the primary cause is well-understood and largely preventable.

The HPV connection

The vast majority of anal cancers — approximately 90% — are caused by human papillomavirus (HPV), specifically high-risk strains including HPV-16 and HPV-18.

HPV is the most common STI globally. Most HPV infections clear on their own without causing any lasting harm. But persistent infection with high-risk strains can cause cellular changes over time — and in the anal canal, those changes can eventually develop into cancer if not detected and treated early.

This is the same mechanism by which HPV causes cervical cancer — which is why the public health tools developed for cervical cancer prevention (vaccination, screening) are directly applicable to anal cancer prevention.

Who is at higher risk?

Gay and bisexual men have significantly elevated rates of anal cancer compared to the general population. Research suggests the incidence of anal cancer among men who have sex with men is comparable to the incidence of cervical cancer in women before widespread cervical screening programmes were introduced — which gives a sense of the scale of the disparity.

People living with HIV — regardless of sexual orientation — are at substantially elevated risk of anal cancer. HIV-related immune suppression impairs the body's ability to clear HPV infection, allowing high-risk strains to persist and cause cellular changes more readily. Among HIV-positive gay and bisexual men, the risk is elevated further.

Trans women — particularly those who engage in receptive anal sex — face similar risk profiles to gay and bisexual men and should be considered for the same screening and prevention approaches.

Anyone who has engaged in receptive anal sex over their lifetime has potential exposure to anal HPV, regardless of their sexual orientation or gender identity.

Why anal cancer is often diagnosed late

Several factors contribute to anal cancer being diagnosed at later stages than it might otherwise be.

Symptoms — including anal bleeding, pain, itching, or a lump — can be mistaken for more common conditions like hemorrhoids or fissures, and may not prompt immediate medical attention. Many people are embarrassed to discuss anal symptoms with a healthcare provider. And many providers don't proactively screen for anal cancer or ask about relevant risk factors.

The result is that by the time anal cancer is diagnosed, it has often progressed further than it would have if detected earlier. Early-stage anal cancer has significantly better treatment outcomes than advanced disease.

Screening — what exists and who should consider it

Unlike cervical cancer, there is no universally implemented screening programme for anal cancer. But the tools exist — and recommendations are increasingly clear about who should consider them.

Anal Pap smear (anal cytology) — similar to a cervical smear, this involves collecting cells from the anal canal for examination. It can detect abnormal cellular changes before they develop into cancer.

High-resolution anoscopy (HRA) — a more detailed examination of the anal canal, used when abnormal cells are detected on an anal Pap smear.

Current guidance from several major health organisations recommends annual anal cancer screening for HIV-positive gay and bisexual men, and consideration of screening for HIV-negative gay and bisexual men and other higher-risk individuals. However, implementation varies significantly by country and healthcare setting.

If you're in a higher-risk group and haven't discussed anal cancer screening with a healthcare provider, it's worth raising — particularly with an LGBTQ+-affirming provider who understands the relevant risk factors.

Prevention — what actually works

HPV vaccination is the most powerful preventive tool available. Current vaccines protect against the high-risk HPV strains most associated with anal cancer — including HPV-16 and HPV-18. The vaccine is most effective when given before first exposure to these strains, but can still provide protection for adults who haven't yet been exposed to the strains it covers.

In many countries, the HPV vaccine is now available to gay and bisexual men through sexual health clinics, regardless of age — because their ongoing risk of HPV exposure through anal sex persists throughout life. If you haven't been vaccinated, this is worth looking into.

Regular STI testing — while not directly protective against HPV or anal cancer, regular testing as part of a broader sexual health routine means engaging with healthcare systems that can identify risk factors and facilitate access to appropriate screening.

Condoms reduce HPV transmission risk, though they don't cover all the skin areas where HPV can be present. They provide meaningful but incomplete protection.

Where CLEAR™ fits in

CLEAR™'s at-home Ship Kit doesn't test for HPV or screen for anal cancer directly — these require specific clinical examinations that can't be replicated through sample collection at home.

What CLEAR™ does provide is comprehensive STI screening — including HIV, chlamydia, gonorrhea, syphilis, and hepatitis B and C — that supports the broader sexual health picture for LGBTQ+ individuals at higher risk of anal cancer.

For people in higher-risk groups, understanding your full sexual health status — including HIV status, which directly affects anal cancer risk — is an important part of a complete health approach. CLEAR™ makes that comprehensive screening private, accessible, and lab-certified — results in 48 hours. 🤍

🔗 Learn more via the link in Bio.

Getting the care you need

If you're in a higher-risk group for anal cancer and haven't discussed screening with a healthcare provider, the starting point is finding an LGBTQ+-affirming provider or sexual health clinic where you can have an open conversation about your risk factors and what screening options are available in your area.

You shouldn't have to educate your provider about why this is relevant. But in clinical environments that aren't familiar with LGBTQ+ health needs, you may need to be direct about requesting anal cancer screening specifically.

Bottom line

Anal cancer is significantly more common in certain LGBTQ+ populations than in the general public — and it's largely preventable with vaccination and detectable early with appropriate screening. The gap between the risk and the awareness is one that accurate information can help close. Vaccination, screening, and regular sexual health care are the three pillars of addressing it effectively. 🏳️‍🌈🤍

The information in this article is intended for general educational purposes only and does not constitute medical advice. Please consult a qualified healthcare professional for personal medical guidance.